Outcome of HAART for patients with CD4<50

David Haburchak

Research output: Contribution to journalArticle

Abstract

Objective: To examine the outcome and cost effectiveness of HAART in AIDS patients with CD4<50. Design: Prospective outcome comparison of benchmark cohorts. Participants: All AIDS patients seen at least one time in clinic with CD4<50 Jan 92-Apr 94 (Cohort 1, N=112) and period 1 Jan- 31 Dec 96 (Cohort 2, N=140). Intervention: Antiretroviral regimens were prescribed by 4 ID physicians based on individual patient clinical situation. Patients were defined as having "triple" therapy if prescribed 2RT+1PI for two months or more, "dual" if 2RT- no PI. Results: Pt months observed Cohort 1: 1961 mo., Cohort 2: 1522 mo. Effectiveness therapy (n) Cohort 1(1992-4) mono (112) Cohort 2 (1996) all(140) triple (71) dual (32)mono(16)no(21) CD4 rise over 50 2% 32% 52% 19% 12% 0% CD4 rise over 100 0% 16% 30% 3% 0 0% viral load < 500 NA 17% 27% 12% 6% 0% median survival from CD4<50 (months) 22 23.5 32.5 21.5 11.5 15.2 Prophylaxis failures % (94 vs 96): PCP (6,1.4); Crypto (4,2); Toxo (8,0);MAC (31,4) cohort 1 cohort 2 Resource Use (n) deaths (62) deaths(46) alive(81) triple dual mono no Admissions/month .17 .20 .06 .06 .10 .15 .24 Hosp days/month 1.57 1.53 .44 .44 .79 1.11 2.00 Clinic visits/month .70 .66 .56 .61 .50 .70 .57 Viral loads/month ND .15 .22 .24 .20 .15 .07 Estimated monthly cost $2720 2800 1666 1650 2079 3280 Conclusion: Selective HAART therapy in patients with CD4$50 is associated with prolonged survival, decreased resource utilization, and decreased monthly cost.

Original languageEnglish (US)
Number of pages1
JournalClinical Infectious Diseases
Volume25
Issue number2
StatePublished - Dec 1 1997

Fingerprint

Highly Active Antiretroviral Therapy
Viral Load
Acquired Immunodeficiency Syndrome
Costs and Cost Analysis
Benchmarking
Survival
Ambulatory Care
Cost-Benefit Analysis
Therapeutics
Physicians

ASJC Scopus subject areas

  • Immunology

Cite this

Outcome of HAART for patients with CD4<50. / Haburchak, David.

In: Clinical Infectious Diseases, Vol. 25, No. 2, 01.12.1997.

Research output: Contribution to journalArticle

Haburchak, David. / Outcome of HAART for patients with CD4<50. In: Clinical Infectious Diseases. 1997 ; Vol. 25, No. 2.
@article{a4f7db40cdaf4917bf6c95a7e108644e,
title = "Outcome of HAART for patients with CD4<50",
abstract = "Objective: To examine the outcome and cost effectiveness of HAART in AIDS patients with CD4<50. Design: Prospective outcome comparison of benchmark cohorts. Participants: All AIDS patients seen at least one time in clinic with CD4<50 Jan 92-Apr 94 (Cohort 1, N=112) and period 1 Jan- 31 Dec 96 (Cohort 2, N=140). Intervention: Antiretroviral regimens were prescribed by 4 ID physicians based on individual patient clinical situation. Patients were defined as having {"}triple{"} therapy if prescribed 2RT+1PI for two months or more, {"}dual{"} if 2RT- no PI. Results: Pt months observed Cohort 1: 1961 mo., Cohort 2: 1522 mo. Effectiveness therapy (n) Cohort 1(1992-4) mono (112) Cohort 2 (1996) all(140) triple (71) dual (32)mono(16)no(21) CD4 rise over 50 2{\%} 32{\%} 52{\%} 19{\%} 12{\%} 0{\%} CD4 rise over 100 0{\%} 16{\%} 30{\%} 3{\%} 0 0{\%} viral load < 500 NA 17{\%} 27{\%} 12{\%} 6{\%} 0{\%} median survival from CD4<50 (months) 22 23.5 32.5 21.5 11.5 15.2 Prophylaxis failures {\%} (94 vs 96): PCP (6,1.4); Crypto (4,2); Toxo (8,0);MAC (31,4) cohort 1 cohort 2 Resource Use (n) deaths (62) deaths(46) alive(81) triple dual mono no Admissions/month .17 .20 .06 .06 .10 .15 .24 Hosp days/month 1.57 1.53 .44 .44 .79 1.11 2.00 Clinic visits/month .70 .66 .56 .61 .50 .70 .57 Viral loads/month ND .15 .22 .24 .20 .15 .07 Estimated monthly cost $2720 2800 1666 1650 2079 3280 Conclusion: Selective HAART therapy in patients with CD4$50 is associated with prolonged survival, decreased resource utilization, and decreased monthly cost.",
author = "David Haburchak",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "25",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Outcome of HAART for patients with CD4<50

AU - Haburchak, David

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Objective: To examine the outcome and cost effectiveness of HAART in AIDS patients with CD4<50. Design: Prospective outcome comparison of benchmark cohorts. Participants: All AIDS patients seen at least one time in clinic with CD4<50 Jan 92-Apr 94 (Cohort 1, N=112) and period 1 Jan- 31 Dec 96 (Cohort 2, N=140). Intervention: Antiretroviral regimens were prescribed by 4 ID physicians based on individual patient clinical situation. Patients were defined as having "triple" therapy if prescribed 2RT+1PI for two months or more, "dual" if 2RT- no PI. Results: Pt months observed Cohort 1: 1961 mo., Cohort 2: 1522 mo. Effectiveness therapy (n) Cohort 1(1992-4) mono (112) Cohort 2 (1996) all(140) triple (71) dual (32)mono(16)no(21) CD4 rise over 50 2% 32% 52% 19% 12% 0% CD4 rise over 100 0% 16% 30% 3% 0 0% viral load < 500 NA 17% 27% 12% 6% 0% median survival from CD4<50 (months) 22 23.5 32.5 21.5 11.5 15.2 Prophylaxis failures % (94 vs 96): PCP (6,1.4); Crypto (4,2); Toxo (8,0);MAC (31,4) cohort 1 cohort 2 Resource Use (n) deaths (62) deaths(46) alive(81) triple dual mono no Admissions/month .17 .20 .06 .06 .10 .15 .24 Hosp days/month 1.57 1.53 .44 .44 .79 1.11 2.00 Clinic visits/month .70 .66 .56 .61 .50 .70 .57 Viral loads/month ND .15 .22 .24 .20 .15 .07 Estimated monthly cost $2720 2800 1666 1650 2079 3280 Conclusion: Selective HAART therapy in patients with CD4$50 is associated with prolonged survival, decreased resource utilization, and decreased monthly cost.

AB - Objective: To examine the outcome and cost effectiveness of HAART in AIDS patients with CD4<50. Design: Prospective outcome comparison of benchmark cohorts. Participants: All AIDS patients seen at least one time in clinic with CD4<50 Jan 92-Apr 94 (Cohort 1, N=112) and period 1 Jan- 31 Dec 96 (Cohort 2, N=140). Intervention: Antiretroviral regimens were prescribed by 4 ID physicians based on individual patient clinical situation. Patients were defined as having "triple" therapy if prescribed 2RT+1PI for two months or more, "dual" if 2RT- no PI. Results: Pt months observed Cohort 1: 1961 mo., Cohort 2: 1522 mo. Effectiveness therapy (n) Cohort 1(1992-4) mono (112) Cohort 2 (1996) all(140) triple (71) dual (32)mono(16)no(21) CD4 rise over 50 2% 32% 52% 19% 12% 0% CD4 rise over 100 0% 16% 30% 3% 0 0% viral load < 500 NA 17% 27% 12% 6% 0% median survival from CD4<50 (months) 22 23.5 32.5 21.5 11.5 15.2 Prophylaxis failures % (94 vs 96): PCP (6,1.4); Crypto (4,2); Toxo (8,0);MAC (31,4) cohort 1 cohort 2 Resource Use (n) deaths (62) deaths(46) alive(81) triple dual mono no Admissions/month .17 .20 .06 .06 .10 .15 .24 Hosp days/month 1.57 1.53 .44 .44 .79 1.11 2.00 Clinic visits/month .70 .66 .56 .61 .50 .70 .57 Viral loads/month ND .15 .22 .24 .20 .15 .07 Estimated monthly cost $2720 2800 1666 1650 2079 3280 Conclusion: Selective HAART therapy in patients with CD4$50 is associated with prolonged survival, decreased resource utilization, and decreased monthly cost.

UR - http://www.scopus.com/inward/record.url?scp=33748184155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748184155&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748184155

VL - 25

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -